Rabacfosadine
Rabacfosadine is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
1 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | RABACFOSADINE |
INN | rabacfosadine |
Description | Rabacfosadine, sold under the brand name Tanovea-CA1, is a guanine nucleotide analog used for the treatment of lymphoma in dogs. The drug was granted conditional approval by the U.S. Food and Drug Administration under application number 141-475 for use in treating canine lymphoma in December 2016 pending a full demonstration of effectiveness, and became the first drug to receive full approval for the treatment of canine lymphoma in July 2021.
|
Classification | Small molecule |
Drug class | phosphoro-derivatives |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CCOC(=O)[C@H](C)NP(=O)(COCCn1cnc2c(NC3CC3)nc(N)nc21)N[C@@H](C)C(=O)OCC |
Identifiers
PDB | — |
CAS-ID | 859209-74-8 |
RxCUI | — |
ChEMBL ID | CHEMBL1823518 |
ChEBI ID | — |
PubChem CID | 16047979 |
DrugBank | DB12762 |
UNII ID | M39BO43J9W (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 36 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more